Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ABL103,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
ABL Bio Collaborates to Evaluate ABL103 with KEYTRUDA® For Solid Tumors
Details : The collaboration aims to evaluate ABL103 in combination with MSD's anti-PD-1 therapy, Keytruda (pembrolizumab) in patients with advanced or metastatic solid tumors.
Brand Name : ABL103
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : ABL103,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Biocytogen
Deal Size : Undisclosed
Deal Type : Collaboration
Biocytogen Collaborates With ABL Bio To Develop Bispecific Antibody-Drug Conjugates
Details : The collaboration aims to develop new bispecific antibody-drug conjugates using Biocytogen’s RenLite® mice platform that can produce fully human antibodies with diverse epitopes and high affinity.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 25, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Biocytogen
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TJ-L14B
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : I-Mab Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
Details : TJ-L14B/ABL503, is a differentiated PD-L1 x 4-1BB bispecific antibody, which is investigated in patients with progressive, locally advanced or metastatic solid tumors who are relapsed or refractory following prior lines of treatment.
Brand Name : ABL503
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 10, 2023
Lead Product(s) : TJ-L14B
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : I-Mab Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
ABL Bio Taps into Synaffix ADC Technology to Accelerate Development of Bispecific ADC Products
Details : Under the agreement, ABL Bio will be responsible for the research, development, and commercialization of bispecific ADCs, designed to overcome the limitations of conventional therapeutic ADCs that target only a single antigen on the targeted cancer cell.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 13, 2023
Lead Product(s) : Bispecific Antibody
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lonza and ABL Bio Collaborate in the Development and Manufacture of Bispecific Antibody Product
Details : The collaboration supports the development and manufacturing of ABL Bio’s new bispecific antibody product by leveraging Lonza’s GS Xceed® expression system which includes GS PiggyBac®, a highly efficient transposon-based gene integration technology...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
April 04, 2023
Lead Product(s) : Bispecific Antibody
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Lonza Group
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ABL301
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration
Details : ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.
Brand Name : ABL301
Molecule Type : Large molecule
Upfront Cash : $75.0 million
January 11, 2022
Lead Product(s) : ABL301
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration
Lead Product(s) : ABL111
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : I-Mab Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
Details : The preclinical studies confirmed the unique pharmacodynamic data and safety of TJ-CD4B/ABL111 in animal models and cell cultures and was well tolerated in non-human primates and did not induce a systemic immune response or liver toxicity up to levels of...
Brand Name : TJ-CD4B
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 09, 2021
Lead Product(s) : ABL111
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : I-Mab Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : HFB30132A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : HiFiBiO Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Partnership with ABL Bio supports HiFiBiO Therapeutics' rapid clinical advancement of its SARS-CoV-2 neutralizing antibody, HFB30132A, for the treatment of COVID-19 patients.
Brand Name : HFB30132A
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 14, 2020
Lead Product(s) : HFB30132A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : HiFiBiO Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Themis Bioscience
Deal Size : Undisclosed
Deal Type : Collaboration
Themis Collaborates with ABL Europe to Manufacture its SARS-Cov-2 Vaccine Candidate in France
Details : Themis and ABL Europe have signed an agreement under which ABL will manufacture Themis' vaccine candidate in preparation for clinical trials.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 11, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Themis Bioscience
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?